BioSpace News Archive

Autolus Therapeutics plc announced its financial and operational results for the transition period from October 1 to December 31, 2018.

SK Capital Partners, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced the final close of SK Capital Partners Fund V with total committed capital of approximately $2.1 billion.

eHealth, Inc. is correcting misstatements regarding non-GAAP net income and non-GAAP net income per diluted share for the fourth quarter of 2018, and guidance for non-GAAP net income per diluted share for the full year ending December 31, 2019 in its earnings press release for the quarter and year ended December 31, 2018 that was issued on February 21, 2019.

LOTEMAX SM Is Formulated with SubMicron Technology for Efficient Penetration To Key Ocular Tissues1

Sky and Bradford Facilities Combine for Over 128,000 kg per Year Production Capacity

BRILINTA reduced cardiovascular events in these patients with no prior heart attack or stroke

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that it has dosed the first patient in its multicenter, open-label, Phase 1b/2 study of AST-008 combined with pembrolizumab.

CytoSorbents Corporation announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will participate in a fireside chat to discuss the company at the 8th Annual SVB Leerink Global Healthcare Conference this Wednesday, February 27, 2019 at 10:00AM EST in New York City.

CannTrust Holdings Inc. is pleased to announce that its common shares will begin trading on the New York Stock Exchange.

KalVista Pharmaceuticals, Inc. announced data from a poster presentation given Saturday, February 23, at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 in San Francisco, CA.